3 results
To determine whether treatment with RAD001 10 mg/d plus Sandostatin LAR® prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR® alone in patients with advanced carcinoid tumor.
The most important objective from this investigation is to prevent or substitute the damage which is coused by therapeutical radiation. As it's most likely that the skin damage as a result of therapeutical radiation can be more limited. From…
The objective is to compare the intervention to standardized care PFMT in terms of clinical, economic and satisfaction outcomes. A secondary objective is to develop a prediction model to identify suitable patients who will benefit the most from the…